Oragenics (OGEN) Shares Outstanding (2011 - 2026)
Oragenics' (OGEN) quarterly Shares Outstanding (Entity) came in at $4.3 million in Q1 2026, up 500.89% YoY from $715771.0 in Q1 2025, and up 99.39% on a QoQ basis from $2.2 million in Q4 2025.
Oragenics (OGEN) Shares Outstanding (2011 - 2026) Analysis & Trends
Oragenics (OGEN) has 16 years of Shares Outstanding (Entity) data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 500.89% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 500.89% YoY) and the FY2025 annual result came in at $2.2 million, up 877.34% from the prior year.
- Shares Outstanding (Entity) advanced to $4.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $4.3 million in Q1 2026 to a low of $64670.0 in Q1 2022.
- A 5-year average of $630722.5 and a median of $116524.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) climbed 0.17% — and 2025, when it soared 877.34%.
- Tracing OGEN's Shares Outstanding (Entity) over 5 years: stood at $66968.0 in 2022, then grew by 11.97% to $74982.0 in 2023, then surged by 194.35% to $220709.0 in 2024, then soared by 877.34% to $2.2 million in 2025, then jumped by 99.39% to $4.3 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $4.3 million (Q1 2026), $2.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 4.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.43 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 1.56 Mn |
| Jun 30, 2025 | 731,817.00 |
| Mar 31, 2025 | 607,147.00 |
| Dec 31, 2024 | 220,709.00 |
| Sep 30, 2024 | 217,580.00 |
| Jun 30, 2024 | 150,953.00 |
| Mar 31, 2024 | 116,524.00 |
| Dec 31, 2023 | 74,982.00 |
| Sep 30, 2023 | 78,528.00 |
| Jun 30, 2023 | 67,485.00 |
| Mar 31, 2023 | 67,485.00 |
| Dec 31, 2022 | 66,968.00 |
| Sep 30, 2022 | 64,865.00 |
| Jun 30, 2022 | 64,670.00 |
| Mar 31, 2022 | 64,670.00 |
| Dec 31, 2021 | 62,739.00 |
| Sep 30, 2021 | 64,597.00 |